Legend Biotech (LEGN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Legend Biotech has announced promising results from their Phase 2 and Phase 3 studies of CARVYKTI® in treating multiple myeloma, showing significant improvements in patient outcomes, including deep and durable responses and improved progression-free survival compared to standard therapies. The data, which were presented at key medical conferences, underpin the FDA’s recent approval of CARVYKTI® for use after just one prior line of therapy. Despite strong efficacy, the treatment has also shown a consistent safety profile, with serious adverse events such as cytokine release syndrome and neurologic toxicities.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- Daniel Ives Lifts Palantir (PLTR) to New Street-High Price Target, Stock Hits a Fresh 52-Week High
- “Boeing Has Backed Itself Into a Corner,” Says Union, Boeing Stock (NYSE:BA) Gains Anyway
- “You Received a Refund Within 24 Hours”: Elon Musk Claps Back on Sam Altman’s Refund Request, Tesla Stock (NASDAQ:TSLA) Surges